TREATMENT FOR REDUCING INFLAMMATION
OA: closed
AI-generated summary
Intraperitoneal administration of lidocaine hydrochloride reduces endometriosis implant inflammation by inhibiting MCP-1 activity and macrophage recruitment without significantly affecting TNF-a levels.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50 % or more while not affecting a corresponding TNF-a related activity level by more than 30 % comprises providing a pharmaceutical composition comprising a local anaesthetic, in particular lidocaine hydrochloride, and a pharmaceutically acceptable carrier, administering the composition intraperitoneally to said person, thereby substantially reducing the recruitment of macrophages by MCP-1 released from the endometriosis implant. Also disclosed is a corresponding pharmaceutical composition.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-07-15T06:11:00.801789+00:00